Who
Allan Shaw
Director
Company insider
Files Form 4 as: Director, CalciMedica; Director, Onconetix; Director, Vivus; Director, Akari Therapeutics.
In numbers
- Trades disclosed
- 122
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $117K
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 21 Sep 2015
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,594 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,250 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 27 Aug 2024filed 28 Aug 2024 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 28 Mar 2024filed 22 Apr 2024 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 8 May 2023filed 28 Jun 2023 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 20 Mar 2023filed 22 Mar 2023 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,880 | filing |
| 20 Mar 2023filed 22 Mar 2023 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —744 | filing |
| 19 Aug 2022filed 23 Aug 2022 | ONCO Onconetixoption or derivative · Biotechnology | SEC FORM 4 Code F | $29629,636 at $0.01 | filing |
| 19 Aug 2022filed 23 Aug 2022 | ONCO OnconetixBiotechnology | SEC FORM 4 Code F | $29629,636 at $0.01 | filing |
| 19 Aug 2022filed 23 Aug 2022 | ONCO OnconetixBiotechnology | SEC FORM 4 Sold | $117K29,636 at $3.94 | filing |
| 4 May 2022filed 27 May 2022 | ONCO Onconetixoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,655 at $0.00 | filing |
| 26 Oct 2018filed 29 Oct 2018 | Vivusoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 1 Oct 2018filed 3 Oct 2018 | Vivus | SEC FORM 4 Code M | —139 | filing |
| 1 Oct 2018filed 3 Oct 2018 | Vivus | SEC FORM 4 Code F | $24243 at $5.63 | filing |
| 15 Sep 2018filed 18 Sep 2018 | Vivusoption or derivative | SEC FORM 4 Code M | —139 at $0.00 | filing |
News
09.25.26 -- Biotech Finance And Investor Update With Independent Board Director Allan Shawlifescienceleader.com · 25 Sep 2026Biotech Finance And Investor Update With Independent Board Director Allan Shawlifescienceleader.com · 14 Sep 2026Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending AcquisitionONCO · manilatimes.net · 23 Oct 2026Realbotix Announces Additional Draw under Bridge Loan from OnconetixONCO · brantfordexpositor.ca · 23 Oct 2026Onconetix, Inc. (NASDAQ:ONCO) Stock Short Interest Rises 261.8%ONCO · tickerreport.com · 13 Oct 2026
2 headlines in the last 90 days name Allan Shaw; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.